Cargando…

A Phase II Randomized, Double‐Blind, Placebo‐Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First‐Line Treatment of Pancreatic Adenocarcinoma

LESSONS LEARNED. The safety profile in the gemcitabine/simtuzumab group was similar to that in the gemcitabine/placebo group. The addition of simtuzumab to gemcitabine does not improve clinical outcomes in patients with metastatic pancreatic adenocarcinoma. BACKGROUND. The humanized IgG4 monoclonal...

Descripción completa

Detalles Bibliográficos
Autores principales: Benson, Al B., Wainberg, Zev A., Hecht, J. Randolph, Vyushkov, Dmitry, Dong, Hua, Bendell, Johanna, Kudrik, Fred
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344644/
https://www.ncbi.nlm.nih.gov/pubmed/28246206
http://dx.doi.org/10.1634/theoncologist.2017-0024
_version_ 1782513584160374784
author Benson, Al B.
Wainberg, Zev A.
Hecht, J. Randolph
Vyushkov, Dmitry
Dong, Hua
Bendell, Johanna
Kudrik, Fred
author_facet Benson, Al B.
Wainberg, Zev A.
Hecht, J. Randolph
Vyushkov, Dmitry
Dong, Hua
Bendell, Johanna
Kudrik, Fred
author_sort Benson, Al B.
collection PubMed
description LESSONS LEARNED. The safety profile in the gemcitabine/simtuzumab group was similar to that in the gemcitabine/placebo group. The addition of simtuzumab to gemcitabine does not improve clinical outcomes in patients with metastatic pancreatic adenocarcinoma. BACKGROUND. The humanized IgG4 monoclonal antibody simtuzumab inhibits the extracellular matrix‐remodeling enzyme lysyl oxidase‐like 2 maintaining pathological stroma in tumors. METHODS. Adult patients with metastatic pancreatic adenocarcinoma (mPaCa) were randomly assigned to receive intravenous gemcitabine, 1,000 mg/m(2), in combination with 200 or 700 mg simtuzumab or placebo. Primary endpoint was progression‐free survival (PFS), secondary endpoints included overall survival (OS), objective response rate (ORR), and safety. RESULTS. Of 240 patients, 80 were randomly assigned to gemcitabine/simtuzumab 700 mg, 79 to gemcitabine/simtuzumab 200 mg, and 81 to gemcitabine/placebo. After a median follow‐up of 3.0, 1.9, and 3.4 months for gemcitabine/simtuzumab 700 mg, gemcitabine/simtuzumab 200 mg, and gemcitabine/placebo, respectively, the median PFS was 3.7 months (adjusted hazard ratio [HR], 95% confidence interval [CI], p value vs placebo: 1.09 [0.74–1.61]; p = .73), 3.5 months (1.13 [0.76–1.66], p = .61]), and 3.7 months, respectively. Median OS was 7.6 months (0.83 [0.57–1.22]; p = .28), 5.9 months (1.07 [0.73–1.55]; p = .69), and 5.7 months, respectively. ORRs were 13.9%, 14.5%, and 23.5%, respectively. Simtuzumab was well tolerated. CONCLUSION. The addition of simtuzumab to gemcitabine did not improve clinical outcomes in patients with mPaCa.
format Online
Article
Text
id pubmed-5344644
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher AlphaMed Press
record_format MEDLINE/PubMed
spelling pubmed-53446442017-07-28 A Phase II Randomized, Double‐Blind, Placebo‐Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First‐Line Treatment of Pancreatic Adenocarcinoma Benson, Al B. Wainberg, Zev A. Hecht, J. Randolph Vyushkov, Dmitry Dong, Hua Bendell, Johanna Kudrik, Fred Oncologist Clinical Trial Results LESSONS LEARNED. The safety profile in the gemcitabine/simtuzumab group was similar to that in the gemcitabine/placebo group. The addition of simtuzumab to gemcitabine does not improve clinical outcomes in patients with metastatic pancreatic adenocarcinoma. BACKGROUND. The humanized IgG4 monoclonal antibody simtuzumab inhibits the extracellular matrix‐remodeling enzyme lysyl oxidase‐like 2 maintaining pathological stroma in tumors. METHODS. Adult patients with metastatic pancreatic adenocarcinoma (mPaCa) were randomly assigned to receive intravenous gemcitabine, 1,000 mg/m(2), in combination with 200 or 700 mg simtuzumab or placebo. Primary endpoint was progression‐free survival (PFS), secondary endpoints included overall survival (OS), objective response rate (ORR), and safety. RESULTS. Of 240 patients, 80 were randomly assigned to gemcitabine/simtuzumab 700 mg, 79 to gemcitabine/simtuzumab 200 mg, and 81 to gemcitabine/placebo. After a median follow‐up of 3.0, 1.9, and 3.4 months for gemcitabine/simtuzumab 700 mg, gemcitabine/simtuzumab 200 mg, and gemcitabine/placebo, respectively, the median PFS was 3.7 months (adjusted hazard ratio [HR], 95% confidence interval [CI], p value vs placebo: 1.09 [0.74–1.61]; p = .73), 3.5 months (1.13 [0.76–1.66], p = .61]), and 3.7 months, respectively. Median OS was 7.6 months (0.83 [0.57–1.22]; p = .28), 5.9 months (1.07 [0.73–1.55]; p = .69), and 5.7 months, respectively. ORRs were 13.9%, 14.5%, and 23.5%, respectively. Simtuzumab was well tolerated. CONCLUSION. The addition of simtuzumab to gemcitabine did not improve clinical outcomes in patients with mPaCa. AlphaMed Press 2017-02-28 2017-03 /pmc/articles/PMC5344644/ /pubmed/28246206 http://dx.doi.org/10.1634/theoncologist.2017-0024 Text en © AlphaMed Press; the data published online to support this summary is the property of the authors.
spellingShingle Clinical Trial Results
Benson, Al B.
Wainberg, Zev A.
Hecht, J. Randolph
Vyushkov, Dmitry
Dong, Hua
Bendell, Johanna
Kudrik, Fred
A Phase II Randomized, Double‐Blind, Placebo‐Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First‐Line Treatment of Pancreatic Adenocarcinoma
title A Phase II Randomized, Double‐Blind, Placebo‐Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First‐Line Treatment of Pancreatic Adenocarcinoma
title_full A Phase II Randomized, Double‐Blind, Placebo‐Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First‐Line Treatment of Pancreatic Adenocarcinoma
title_fullStr A Phase II Randomized, Double‐Blind, Placebo‐Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First‐Line Treatment of Pancreatic Adenocarcinoma
title_full_unstemmed A Phase II Randomized, Double‐Blind, Placebo‐Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First‐Line Treatment of Pancreatic Adenocarcinoma
title_short A Phase II Randomized, Double‐Blind, Placebo‐Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First‐Line Treatment of Pancreatic Adenocarcinoma
title_sort phase ii randomized, double‐blind, placebo‐controlled study of simtuzumab or placebo in combination with gemcitabine for the first‐line treatment of pancreatic adenocarcinoma
topic Clinical Trial Results
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344644/
https://www.ncbi.nlm.nih.gov/pubmed/28246206
http://dx.doi.org/10.1634/theoncologist.2017-0024
work_keys_str_mv AT bensonalb aphaseiirandomizeddoubleblindplacebocontrolledstudyofsimtuzumaborplaceboincombinationwithgemcitabineforthefirstlinetreatmentofpancreaticadenocarcinoma
AT wainbergzeva aphaseiirandomizeddoubleblindplacebocontrolledstudyofsimtuzumaborplaceboincombinationwithgemcitabineforthefirstlinetreatmentofpancreaticadenocarcinoma
AT hechtjrandolph aphaseiirandomizeddoubleblindplacebocontrolledstudyofsimtuzumaborplaceboincombinationwithgemcitabineforthefirstlinetreatmentofpancreaticadenocarcinoma
AT vyushkovdmitry aphaseiirandomizeddoubleblindplacebocontrolledstudyofsimtuzumaborplaceboincombinationwithgemcitabineforthefirstlinetreatmentofpancreaticadenocarcinoma
AT donghua aphaseiirandomizeddoubleblindplacebocontrolledstudyofsimtuzumaborplaceboincombinationwithgemcitabineforthefirstlinetreatmentofpancreaticadenocarcinoma
AT bendelljohanna aphaseiirandomizeddoubleblindplacebocontrolledstudyofsimtuzumaborplaceboincombinationwithgemcitabineforthefirstlinetreatmentofpancreaticadenocarcinoma
AT kudrikfred aphaseiirandomizeddoubleblindplacebocontrolledstudyofsimtuzumaborplaceboincombinationwithgemcitabineforthefirstlinetreatmentofpancreaticadenocarcinoma
AT bensonalb phaseiirandomizeddoubleblindplacebocontrolledstudyofsimtuzumaborplaceboincombinationwithgemcitabineforthefirstlinetreatmentofpancreaticadenocarcinoma
AT wainbergzeva phaseiirandomizeddoubleblindplacebocontrolledstudyofsimtuzumaborplaceboincombinationwithgemcitabineforthefirstlinetreatmentofpancreaticadenocarcinoma
AT hechtjrandolph phaseiirandomizeddoubleblindplacebocontrolledstudyofsimtuzumaborplaceboincombinationwithgemcitabineforthefirstlinetreatmentofpancreaticadenocarcinoma
AT vyushkovdmitry phaseiirandomizeddoubleblindplacebocontrolledstudyofsimtuzumaborplaceboincombinationwithgemcitabineforthefirstlinetreatmentofpancreaticadenocarcinoma
AT donghua phaseiirandomizeddoubleblindplacebocontrolledstudyofsimtuzumaborplaceboincombinationwithgemcitabineforthefirstlinetreatmentofpancreaticadenocarcinoma
AT bendelljohanna phaseiirandomizeddoubleblindplacebocontrolledstudyofsimtuzumaborplaceboincombinationwithgemcitabineforthefirstlinetreatmentofpancreaticadenocarcinoma
AT kudrikfred phaseiirandomizeddoubleblindplacebocontrolledstudyofsimtuzumaborplaceboincombinationwithgemcitabineforthefirstlinetreatmentofpancreaticadenocarcinoma